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http://www.ro-journal.com/content/8/1/132RESEARCH Open AccessSalivary gland-sparing other than parotid-sparing
in definitive head-and-neck intensity-modulated
radiotherapy does not seem to jeopardize local
control
Enrique Chajon1*, Caroline Lafond1,2,3, Guillaume Louvel1, Joël Castelli1, Danièle Williaume1, Olivier Henry1,
Franck Jégoux4, Elodie Vauléon1, Jean-Pierre Manens1, Elisabeth Le Prisé1 and Renaud de Crevoisier1,2,3Abstract
Background: The objective was to analyze locoregional (LR) failure patterns in patients with head-and-neck cancer
(HNC) treated using intensity-modulated radiotherapy (IMRT) with whole salivary gland-sparing: parotid (PG),
submandibular (SMG), and accessory salivary glands represented by the oral cavity (OC).
Methods: Seventy consecutive patients with Stage I-II (23%) or III/IV (77%) HNC treated by definitive IMRT were
included. For all LR failure patients, the FDG-PET and CT scans documenting recurrence were rigidly registered to the
initial treatment planning CT. Failure volumes (Vf) were delineated based on clinical, radiological, and histological
data. The percentage of Vf covered by 95% of the prescription isodose (Vf-V95) was analyzed. Failures were classified
as “in-field” if Vf–V95 ≥ 95%, “marginal” if 20% < Vf-V95 < 95%, and “out-of-field” if Vf-V95 ≤20%. Correlation between
Vf-V95 and mean doses (Dmean) in the PG, SMG, and OC was assessed using Spearman’s rank-order correlation test.
The salivary gland dose impact on the LR recurrence risk was assessed by Cox analysis.
Results: The median follow-up was 20 months (6–35). Contralateral and ipsilateral PGs were spared in 98% and 54%
of patients, respectively, and contralateral and ipsilateral SMG in 26% and 7%, respectively. The OC was spared to a
dose ≤40 Gy in 26 patients (37%). The 2-year LR control rate was 76.5%. One recurrence was “marginal”, and 12 were
“in-field”. No recurrence was observed in vicinity of spared structures. Vf-V95 was not significantly correlated with
Dmean in PG, SMG, and OC. The LR recurrence risk was not increased by lower Dmean in the salivary glands, but by
T (p = 0.04) and N stages (p = 0.03).
Conclusion: Over 92% of LR failures occurred “in-field” within the high dose region when using IMRT with a whole
salivary gland-sparing strategy. Sparing SMG and OC in addition to PG thus appears a safe strategy.
Keywords: Head -and-neck cancer, IMRT, Xerostomia, Salivary glandsBackground
Xerostomia is one of the most common and disabling
adverse effects of radiotherapy (RT) for head-and-neck
cancer (HNC), inducing difficulties in swallowing and
speaking, loss of taste, and dental caries, with a direct
impact on patient quality of life [1]. Reducing xerostomia
is a main objective of intensity-modulated RT (IMRT) in* Correspondence: e.chajon@rennes.unicancer.fr
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reproduction in any medium, provided the orHNC. Currently, a modest but significant improvement
in salivary flux parameters and subjective xerostomia has
been confirmed in randomized trials, with only parotid
gland-sparing [2-4].
A potential reduction in the sensation of mouth dry-
ness has been hypothesized provided that other tissues
such as submandibular (SMG) and accessory salivary
glands (represented by the oral cavity [OC] volume) are
spared [5]. A dose-effect relationship of mouth dryness
was demonstrated for SMG with an exponential reduc-
tion in salivary output as mean dose increases beyond aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Demographic, tumor and treatment characteristics
of the 70 patients
Characteristic N (%)
Age (y)
Median 61
Range 41-91
Gender
Male 62
Female 8
Primary site
Oral cavity 8
Oropharynx 31
Hypopharynx 17
Larynx 10
Nasopharynx 3
Unknown primary 1
Tumor stage
T0 1
T1 5
T2 22
T3 25
T4 17
Nodal stage
N0 18
N1 16
N2a 3
N2b 20
N2c 8
N3 5
Overall stage
I 1
II 15
III 9
IV 45
Radiotherapy
Step and Shoot IMRT 65
Volumetric Modulated Arc Therapy 5
Chemotherapy
Concurrent
Cisplatin 22
Carboplatin/5-Fu 7
Cetuximab 12
Induction + concurrent 7
No chemotherapy 22
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unstimulated salivary flow and xerostomia grades were
correlated in prospective studies with contro-lateral
SMG-sparing [7]. However, the SMG and OC are usually
in close relationship with planning target volumes (PTV)
as are the oropharyngeal mucosa and the Level II lymph
nodes. Consequently, there is a risk of under-dosing
these target volumes, which would increase locoregional
(LR) recurrences. In contrast to parotid gland (PG)-spar-
ing IMRT, safety data with SMG- and OC-sparing is
scant. Saarilahti K et al. [8], reported that SMG-sparing
using IMRT is feasible in selected patients, with no can-
cer recurrences observed at the vicinity of spared SMG.
A recent update of this series involving a larger cohort
of patients confirmed the initial results [9].
This report aimed to analyze the LR failure patterns in
HNC patients treated with definitive IMRT using a com-
prehensive approach for salivary gland-sparing, which
integrated in the planning process not only PG but also
SMG and accessory salivary glands represented by OC,
when definitive bilateral neck RT was indicated.
Methods
Patients
Between September 2009 and August 2011, 111 consecu-
tive patients with histologically confirmed squamous cell
carcinoma of head and neck were treated with IMRT at
the Eugene Marquis Cancer Center radiotherapy depart-
ment (Rennes, France). Overall, 41 patients who received
postoperative IMRT or unilateral neck irradiation were
excluded from analysis. The remaining 70 who received
definitive and bilateral neck IMRT were analyzed.
Of the 70 patients, 54 exhibited locally-advanced AJCC
(American Joint Committee on Cancer) Stage (III-IV)
disease and 16 early-stage (I-II) disease. The patient
clinical characteristics are summarized in Table 1. Sta-
ging evaluation included complete history and phys-
ical examination, appropriate endoscopic examination
under anesthesia, which consisted of biopsy with de-
tailed disease mapping and contrast-enhanced com-
puted tomography (CT) scan of head, neck, and thorax.
The 18-fluorodeoxyglucose (FDG) positron emission tom-
ography (PET)-CT scans were obtained before treatment
start, 3 months after the end of RT, and in case of
suspected recurrence.
Radiotherapy
All patients received definitive external beam RT using
step and shoot IMRT or volumetric modulated arc ther-
apy (VMAT). Patients were immobilized in supine pos-
ition with custom aquaplast masks holding both neck
and shoulders. CT contrast-enhanced images indexed
every 2-3 mm were acquired extending from the vertex
to the carina (Brilliance, Big Bore, Philips, Netherlands).
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slice by slice on CT images. The gross tumor volume
(GTV) was defined by clinical examination, computed
tomography, and FDG-PET scan. The GTV encompassed
all visible and palpable primary and nodal diseases. The
high-risk clinical target volume (CTV) was defined by
GTV plus areas potentially containing microscopic
disease limited by anatomic barriers or by GTV plus
10 mm margin when an anatomic barrier was not
clearly identified (ex: tongue base), or when the lymph
node levels containing involved lymph nodes and
neighboring node levels were considered at risk of sub-
clinical involvement greater than 15-20% [10]. The
low-risk CTV encompassed the remaining lymph node
areas considered at low-risk (greater than 5%) for po-
tential microscopic spreading [11,12]. The planning
target volume (PTV), aimed to account for setup un-
certainties, was defined using an additional margin of
5 mm around the GTV (PTV66 or 70), the high-risk CTV
(PTV60 or 63), and the low-risk CTV (PTV54 or 56).
Patients with Stage I-II disease were treated with a
simultaneously modulated accelerated RT (SMART)
technique: The dose prescribed was 66Gy in 2.2Gy
daily fractions over 30 days to the PTV66; 60Gy in
2Gy daily fractions to the PTV60; and 54Gy in 1.8Gy
daily fractions to the PTV54 [13].
Patients with locally-advanced disease (Stage III-IV)
were treated with a simultaneously integrated boost
(SIB) technique: The dose prescribed was 70Gy in 2Gy
daily fractions over 35 days to the PTV70; 63Gy in
1.8Gy daily fractions to the PTV63; and 56Gy in 1.6Gy
daily fractions to the PTV56 [11].
OAR included the spinal cord, brainstem, mandible,
larynx, bilateral inner ears, esophagus, pharyngeal con-
strictors, OC, parotid glands, and SMG. In nasopharyn-
geal, oropharyngeal or laryngeal cancer cases, selective
Level IB-sparing was considered in the N0 neck or if
Level II was not grossly involved (no more than 1–2
lymph nodes of no more than 3 cm in diameter). In pa-
tients with well-lateralized primary OC (gingivobuccal
mucosa or alveolar ridge) tumors and early stage, select-
ive controlateral SMG-sparing was also considered.
Dosimetric considerations
Treatment planning was carried out on the Pinnacle
(Version 9.0) treatment planning system, using 6MV
photon beams from an Elekta Synergy linear accelerator.
The highest priority was assigned to PTVs with the fol-
lowing constraints: more than 95% of any PTV should
receive more than 95% of the prescribed dose or more
than 98% of any PTV should receive more than 90% of
the prescribed dose; no more than 20% of any PTV
could receive more than 110% of the prescribed dose; no
more than 1% or 1 cm3 of the tissue outside the PTVshould receive more than 110% of the dose prescribed to
the primary dose target (PTV 70 or 66).
The following OAR dose constraints were used [14]:
brainstem and spinal cord maximum doses (D2%) were
50Gy and 45Gy, respectively; for the parotid glands,
mean dose (D mean) was <26Gy or the maximum dose
received by 50% of the volume was <30Gy; for the SMG,
D mean was ≤39Gy; for OC (defined as previously de-
scribed by Eisbruch et al. [5]), D mean was as low as
possible; for the larynx, D mean was ≤45 Gy; for the
pharyngeal constrictors, D mean was ≤40 Gy; for the
esophagus, D mean was ≤35 Gy; for the inner ears, D
mean was ≤40Gy; for the mandible, D2% was ≤65Gy.
Definition and dosimetric analysis of failure volumes (Vf)
For all patients with local or regional failure, FDG-PET
and CT scans of the recurrence were rigidly registered
to the initial treatment planning CT data set using Pin-
nacle Version 9.2. Failure volumes (Vf ) were defined
and delineated taking into account clinical, radiological,
and histological data. Dose-volume histograms (DVH)
were calculated in order to analyze the dose of irradi-
ation received by Vf. Failures were classified as “in-field”
if >95% of Vf was covered by 95% of the prescription iso-
dose (as shown in Figure 1), as “marginal” if 20%-95% of
Vf was encompassed by 95% of the prescription isodose
(as shown Figure 2), and as “out-of-field” if <20% was
contained within the 95% of corresponding PTV isodose
line [15].
Statistical analysis
Cumulative incidence of LR failure and overall survival
(OS) were estimated using the Kaplan-Meier method.
The relapse time to treatment failure was calculated
using the first RT day as the starting point. Persistent
disease was defined if tumor presence was proven within
6 months following RT completion. Disease recurrence
was defined as tumor appearing more than 6 months
after therapy completion. Correlation between Vf-V95
and mean doses in salivary glands (PG, SMG, and OC)
was assessed using Spearman test. The impact of dose
parameters on LR recurrence risk was assessed by Cox
analysis.
All analyses were performed using Statistical Package
for the Social Sciences, Version 10.0 (SPSS, Chicago IL).
Results
Failure patterns
The median time from treatment to last follow-up was
20 months (6 to 35 months). The 2-year Kaplan-Meier
cumulative incidence of LR control and OS were 76.5%
(95% confidence interval [CI]: 69-89%) and 95% (95% CI:
90-100%), respectively. Of the 16 patients who presented
disease-related events, 13 exhibited LR failures and three
Figure 1 Example of in-field recurrence. The planning CT has been registered with the FDG-PET-CT imaging of the recurrence. The failure
volume (Vf ) appears fully within the 95% PTV isodose (a and b). The Vf-V95 is equal to 99.9% (c).
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tients who developed LR failures, four displayed isolated
local failure, four isolated regional failure, two local and
regional failures, and the remaining three simultaneous
LR and distant relapses. The clinical and dosimetric
characteristics of the 13 LR failure patients are summa-
rized in Table 2.
Almost all recurrences occurred in previous disease
areas. Only 1 of the 13 LR relapse patients exhibited a mar-
ginal failure, with the remaining 12 presenting with truly
in-field failure within the high-dose region (PTV66-70).
None of the study cohort patients had out-of-field LR fail-
ure. In the marginal failure patient, local recurrence devel-
oped in the primary site initially covered by 95% of 70Gy
isodose. There was only one recurrence in the contralateral
neck. This patient with persistent T2N2bM0 laryngeal
squamous cell carcinoma underwent total laryngectomy
with bilateral neck dissection. The final pathology report
confirmed LR disease persistence, with metastatic disease
in a solitary small node involving contralateral Level IVnodal region considered at low-risk of subclinical disease
(PTV56) in the RT treatment plan. In none of the patients
relapse occurred in the vicinity of the spared parotid gland
or SMG, or in the spared OC.
Surgical salvage for LR failure (either persistent or re-
current disease) was attempted in five patients.
Salivary gland-sparing
Contralateral parotid glands were spared in 98% of pa-
tients, and ipsilateral parotids in 54%. Concerning SMG,
18 (26%) contralateral glands were spared, and ipsilateral
SMG were deemed to have been spared in only five. In
these patients, ipsilateral Levels II and III were consid-
ered at low-risk, and the RT dose was 54-56Gy. In the
other 13 (19%) patients, doses to the SMG were below
50Gy. The OC was spared to a dose ≤40Gy in 26 patients
(37%), and to a dose <50Gy in another 30% (21 patients).
Dosimetric data is detailed in Table 3.
Xerostomia was assessed according to radiation ther-
apy oncology group (RTOG) criteria [16]. At the last
Figure 2 Example of marginal recurrence. The planning CT has been registered with the FDG-PET-CT imaging of the recurrence. The failure
volume (Vf ) appears partially outside the 95% PTV isodose (a and b). The Vf-V95 is equal to 50% (c).
Table 2 Characteristics and dose volume data for patients with a locoregional failure
No. Primary site T stage N stage V95 of the PTV Location of the Vf Vf-V95* (site of failure) Time to recurrence (months)
1 Oropharynx T3 N2b 95% In-field 99% (N) 8
2 Larynx T2 N2c 93% In-field 99% (N) persistence
3 Oral cavity T4 N2c 92% In-field 99% (T) persistence
4 Larynx T3 N2c 95% Marginal 50% (T) 9
5 Oropharynx T4 N3 97% In-field 100% (T + N) 7
6 Oral cavity T4 N0 98% In-field 99% (T) 16
7 Hypopharynx T3 N2c 96% In-field 94% (N) 15
8 Oropharynx T3 N2b 89% In-field 100% (N) 15
9 Oropharynx T3 N1 96% In-field 100% (N) persistence
10 Oral cavity T3 N2a 96% In-field 95% (T + N) 10
11 Larynx T2 N2b 95% In-field 100% (T) 100% (N) persistence
12 Oropharynx T3 N2b 97% In-field 99% (T) 8
13 Hypopharynx T3 N2b 99% In-field 100% (T + N) 9
Abbreviations: Vf failure volume; T Tumor; N Node, * Percentage of Vf covered by 95% of the prescription dose.
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Table 3 Mean doses to the spared salivary glands and oral cavity by primary tumor site
Tumor site Patients (nb) Ipsilateral PG Contralateral PG Ipsilateral SMG Contralateral SMG OC
No. of spared
glands
Mean dose Gy
(range)
No. of spared
glands
Mean dose Gy
(range)
No. of spared
glands
Mean dose Gy
(range)
No. of spared
glands
Mean dose Gy
(range)
Nb Mean dose Gy
(range)
Oral cavity 8 5 31 (29.4-32.5) 8 27.1 (16–31.7) NS NA NS NA NS NA
Oropharynx 31 12 28.6 (25–31.5) 30 27.5 (23.6-32.2) 2 35.5 (33–38) 8 33.8 (29–36.5) 5 34.2 (29.7-38.2)
Hypopharynx 17 9 28.9 (24.4-31.5) 17 27.6 (22.9-34.4) 1 39.6 4 36.1 (28.7-39.5) 9 34.8 (30.5-40)
Larynx 10 9 26.8 (20.7-33.2) 10 25 (19.1-30.1) 1 34.9 3 36.7 (34–39) 9 30.5 (23–39.7)
Nasopharynx 3 2 30.2 (30.4-30) 3 27.8 (26.7-28.7) 1 38 2 33.1 (30.3-35.8) 3 33.5 (29.7-35.2)
Unknown primary 1 1 32.5 1 17.3 NS NA 1 28 1 44.3
Abbreviations: PG parotid gland; SMG submandibular gland; OC oral cavity; NS Non spared; NA Non applicable.
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Grade 3 permanent xerostomia, and 18.4% presented
Grade 2 xerostomia.
Correlation test and impact of dose parameters on local
recurrence risk
In LR failure patients, Vf-V95 did not significantly cor-
relate with the mean dose in both the ipsilateral and
contralateral salivary glands (PG, SMG, and OC). The
primary cancer stage and N stage were the only parame-
ters significantly increasing local failure risk (p = 0.04
and p = 0.03, respectively). The LR recurrence risk was
increased neither by lower dose in the salivary glands
nor by PTV coverage (V95).
Discussion
This report aimed to analyze failure patterns in HNC pa-
tients treated with a comprehensive approach for salivary
gland-sparing using definitive IMRT. With 2-year LR con-
trol rates of 76.5% and OS of 95%, the treatment outcomes
presented in this report are consistent with those of other
patient series treated with parotid-sparing RT [15,17,18].
The recently-published randomized PARSPORT trial has
proved that both objective and subjective xerostomia was
significantly improved when parotid gland-sparing IMRT
was compared with conventional RT [3]. However, there
was concern about the higher number of locoregional re-
currences in the IMRT arm (12 patients in the IMRT arm
versus seven in the conventional arm). Though this differ-
ence was not statistically significant, some questions have
been raised regarding treatment reproducibility in different
centers, evaluation methodology for locoregional tumor
extension, as well as delivery accuracy of IMRT. As part of
quality control practices, individual center evaluation ap-
pears appropriate when a new treatment approach is
adopted. On the whole, the number of marginal recur-
rences published in scientific literature was around 1.5%,
depending on the series [19]. In our study, almost all recur-
rences occurred in-field in the high-dose volume region,
and there was only one marginal recurrence. In none of
the patients did recurrence occur in the vicinity of the par-
otid glands, SMG, or OC that were supposed to be spared.
Even if our series comprised a relatively limited number of
recurrences, this in-field high-dose recurrence rate
data allows us to conclude that local control was not
compromised by SMG, OC, and parotid gland-sparing
strategy. Patterns of failure may depend also on the pri-
mary tumor sites thus an increase in the number of pa-
tients by tumor sites would have refined the results. A high
Evidence-Based Medicine level would have however imply
a non-inferiority design of the study.
Scarce data has been published concerning the safety
of both SMG and OC preservation. A series published
by Saarilahti et al. [8], and recently updated by Collanet al. [9] involving 80 patients treated using definitive
RT (49%) and post-operative RT (51%) with the objective
of parotid gland and SMG-sparing, showed no recur-
rences in the vicinity of spared structures, with mean
doses ≤33.6Gy to SMG. Achieving such dose levels with-
out underdosing the neighboring PTV is a challenge,
particularly in patients with locally-advanced disease
(77% in our study) who are unsuitable for surgical ther-
apy. Without a doubt, the most reliable prognostic infor-
mation is obtained from the pathology report when
surgery is the primary management method. In the post-
operative setting, dose levels are accurately adapted de-
pending on the risk level. Given this context, other
options for SMG-sparing have been explored. For in-
stance, SMG transfer prior to RT could be an option for
patients scheduled to undergo primary surgery with low-
risk of contralateral lymph node Level IB involvement.
This surgical technique has recently proven to be repro-
ducible in a multicenter setting [20,21].
The key role of SMG and minor salivary glands in the
production of unstimulated saliva and in subjective sen-
sations of xerostomia is today well-recognized [5,22].
Dose levels administered to SMG and minor salivary
glands represented by the OC were identified to be sig-
nificant predictors of patient-reported xerostomia 5.
More recently, Little et al. [22] showed xerostomia to be
favorably affected by reducing the dose administered to
all salivary glands other than parotid. Low patient-
reported and observer-graded xerostomia was observed
if the contralateral SMG mean dose was <50Gy and the
OC mean dose <40Gy in patients whose bilateral parotid
glands were spared as much as possible.
In our study involving mainly patients with locally-
advanced disease, contralateral parotid glands were
spared in 98% of patients, and ipsilateral parotid glands
in 54%. Only 26% of contralateral SMG were spared to
a dose <39Gy, because lymph node Level II was fre-
quently considered at high-risk and treated to a dose of
60-63Gy. However, doses <50Gy were achieved in 51%
of SMG. Achieving dose levels <50Gy to SMG when
radical RT is used as primary therapeutic modality is
presumed more realistic than <39Gy. In addition, we
were able to keep mean doses to the OC <40Gy in 37%
of patients. The SMG could not be spared mainly for
OC primaries in our series, since they were not well
lateralized and they were advanced stage. The majority
of the small OC tumors are usually treated by surgery.
In relation to OC-sparing, it should be noted that a
substantial proportion of patients (44%) presented with
oropharyngeal primary tumors and 11% with oral cavity
primary tumors, which exposed this structure to high-
dose levels.
As for xerostomia, although our retrospective study
has its limitations, we would like to highlight that only
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exhibiting Grade 3 xerostomia. These results are consid-
erably more favorable than those of another randomized
study reporting Grade ≥2 xerostomia in 38% [3]. How-
ever, prospective trials must be undertaken to assess the
final impact on patient quality of life.
Taking all the above points into consideration, it seems
reasonable to maintaining mean doses of RT to the OC
and SMGs as low as possible, in addition to parotid glands.
Yet, for this approach, patients must be carefully selected.
Sanguineti et al. [12] identified a non-significant risk (<5%)
of Level IB involvement, even in patients with multiple
positive neck levels suffering from early-stage oropharyn-
geal carcinomas. Eisbruch et al. [23] recommended that in
nasopharyngeal, oropharyngeal or laryngeal cancer cases,
selective Level IB-sparing could be considered if Level II is
not grossly involved. Having followed these recommenda-
tions in our clinical practice, our study findings revealed
that a comprehensive approach for salivary gland-sparing
in definitive IMRT may constitute a safe strategy. Yet the
safety of this approach must be confirmed by other larger-
scale prospective studies.
Conclusion
Locoregional control does not appear to be compromised
by SMG and OC-sparing, in addition to parotid gland-
sparing, in HNC patients treated using definitive IMRT.
Most LR recurrences were in-field and located in regions
covered by 95% of the prescription dose. As our series does
not reveal a higher recurrence rate, our strategy consisting
of sparing not only the parotid glands but also SMG and
OC appears to be safe.
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